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ABSTRACT
One of the properties of human breast cancer cells is cancer stemness, which 
is characterized by self-renewal capability and drug resistance. Protein kinase D1 
(PRKD1) functions as a key regulator of many cellular processes and is downregulated 
in invasive breast cancer cells. In this study, we found that PRKD1 was upregulated in 
MCF-7-ADR human breast cancer cells characterized by drug resistance. Additionally, 
we discovered that PRKD1 expression was negatively regulated by miR-34a binding 
to the PRKD1 3′-UTR. PRKD1 expression increased following performance of a 
tumorsphere formation assay in MCF-7-ADR cells. We also found that reduction 
of PRKD1 by ectopic miR-34a expression or PRKD1 siRNA treatment resulted 
in suppressed self-renewal ability in breast cancer stem cells. Furthermore, we 
confirmed that the PRKD1 inhibitor CRT0066101 reduced phosphorylated PKD/PKCμ, 
leading to suppression of breast cancer stemness through GSK3/β-catenin signaling. 
PRKD1 inhibition also influenced apoptosis initiation in MCF-7-ADR cells. Tumors from 
nude mice treated with miR-34a or CRT0066101 showed suppressed tumor growth, 
proliferation, and induced apoptosis. These results provide evidence that regulation 
of PRKD1, a novel miR-34a target, contributes to overcoming cancer stemness and 
drug resistance in human breast cancer.
INTRODUCTION
Breast cancer is the most common type of cancer 
and the leading cause of cancer-related death in women 
worldwide [1]. Despite efforts to improve patient survival 
rates, problems associated with breast cancer therapy, 
including cancer metastasis and drug resistance, remain [2, 
3]. Tumors are organized with cancer stem cells (CSCs) 
and non-tumorigenic cells forming a tumor mass [4]. CSCs 
are considered the cause of tumors, cancer metastasis, 
drug resistance, and cancer relapse [5]. Specifically, CSCs 
in breast cancer (BCSC) display stem-cell properties and 
are characterized by expression of the cell-surface marker 
CD44+/CD24- [6]. Different miRNAs are involved in 
the formation and regulation of human BCSCs [7], with 
previous studies reporting that ectopic expression of miR-
34c suppressed epithelial–mesenchymal transition and 
reduced self-renewal capacity in BCSCs [8].
The serine/threonine-protein kinase D1 (PRKD1) 
functions as diacylglycerol and protein kinase C (PKC) 
effectors that mediate the actions of stimuli [9]. Processes 
associated with protein kinase D (PKD)/PKCμ were 
activated by two phosphorylation loops through PKC-
dependent phosphorylation (Ser744/Ser748) and PKC-
independent autophosphorylation (Ser910) [10-13]. 
Therefore, PRKD1 is considered as a key regulator of 
many cellular processes, including initiation of the NF-kB 
signaling pathway, enhancement of cell cycle progression 
and DNA synthesis, and regulation of other pathological 
conditions [14-16].
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MicroRNA regulates apoptosis, tumorigenesis, and 
angiogenesis in breast cancer. A key regulator of tumor 
suppression, miR-34 is a direct transcriptional target of the 
tumor suppressor p53, given that the miR-34a promoter 
region contains a p53-binding site [17]. In breast cancer 
studies, miR-34a played a role in preventing cell survival 
by upregulating p53 post-irradiation after DNA had 
been damaged [18]. Additionally, miR-34a promoted 
cancer-cell apoptosis by targeting Bcl-2 and SIRT1 [19]. 
Therefore, miR-34a may be associated with targets that 
induce breast cancer.
In this study, we found that overexpressed PRKD1 
was inhibited by miR-34a in MCF-7-ADR cells. 
Furthermore, PRKD1 activated the self-renewal capacity 
in BCSCs through glycogen synthase kinase 3 (GSK3)/β-
catenin signaling, and contributed to the elimination of drug 
resistance. These results suggest important roles for PRKD1, 
a novel miR-34a target, in human breast cancer therapy.
RESULTS
miR-34a suppresses PRKD1 in 
MCF-7-ADR cells
We evaluated PRKD1 expression in breast cancer cell 
lines, including MCF-10A, MCF-7, ZR-75-1, MCF-7-ADR, 
SK-BR-3, MDA-MB-231, and MDA-MB-468. The results 
indicated increased PRKD1 expression levels in MCF-7-
ADR cells (Figure 1A). We determined possible miRNAs 
capable of regulating PRKD1 by using microRNA prediction 
online databases [miRanda (http://www.microrna.org/
microrna/home.do) and TargetScan (http://www.targetscan.
org/)]. Given that miR-34 was a candidate regulator, 
we determined PRKD1 mRNA expression and protein 
translation levels following ectopic expression of miR-34a, 
miR-34b, and miR-34c. Although miR-34a, miR-34b, and 
miR-34c have the same seed sequence, the results indicated 
Figure 1: PRKD1 is a novel miR-34a target. A. PRKD1 mRNA expression and miR-34a expression was quantified by qRT-PCR in 
various breast cancer cell lines. B. Proteins, mRNAs and totalRNAs were obtained after 48-h transfection of miRNA-34 variants. Western 
blots are representative of three independent experiments. β-actin was used as the loading control and qRT-PCR was performed to validate 
PRKD1 mRNA and miR-34 variant expression. The levels of miR-34a, b and c expression were detected following ectopic expression of 
miR-34a, b and c, respectively. C. Predicted miR-34a binding site and reporter constructs from the wild-type/mutant PRKD1 3′-UTR. The 
activities of the 3′-UTR reporter constructs were normalized to the activity of co-transfected phRL-Luc vector. The graphs show mean ± 
S.D. (error bars) from three independent experiments. * p < 0.05; ** p < 0.001; *** p < 0.0001.
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that PKD/PKCμ was downregulated only by miR-34a 
(Figure 1B). To confirm the miR-34a binds to the PRKD1 
3′-UTR, we mutated the predicted miR-34a binding site 
on the PRKD1 3′-UTR and inserted the mutated sequence 
into a pGL3-control vector (Figure 1C). As shown in Figure 
1C, overexpression of miR-34a inhibited the luciferase 
activity of the PRKD1 wild-type sequence, but not that 
of the mutants in MCF-7-ADR cells. We screened for the 
levels of miR-34a expression in breast cancer cell lines, and 
consistent with the results shown in Figure 1A, miR-34a was 
downregulated in MCF-7-ADR cells. These results indicate 
that miR-34a negatively regulates PRKD1 (Figure 1A).
Expression levels of miR-34b and miR-34c were also 
detected, however, no significant downregulation of either 
variant in MCF-7-ADR cells was observed (Supplementary 
Figure 1A, 1B). These results suggest that PRKD1 is 
downregulated by miR-34a in MCF-7-ADR cell lines.
PRKD1 stimulates breast cancer stemness 
through GSK3/β-catenin signaling
To determine the effects of PRKD1 inhibition 
on CSCs, MCF-7-ADR cells were transfected with 
miR-34a precursors and PRKD1 siRNAs. Following 
transfection, miR-34a expression levels increased and 
PKD/PKCμ levels decreased relative to negative control 
(Figure 2A). PRKD1 expression levels also decreased 
following PRKD1 siRNA transfection as compared to 
levels observed in association with transfection of control 
siRNA. Interestingly, PKD/PKCμ levels also decreased 
following PRKD1 siRNA transfection (Figure 2B). We 
checked efficiency of three different PRKD1 siRNAs to 
exclude unspecific effects and we selected PRKD1 siRNA 
#1, which was shown high suppression of PRKD1 relative 
with the others (Supplementary Figure 2).
PRKD1 phosphorylation of β-catenin at Thr112/
Thr120 could be critical for cell-cell adhesion in prostate 
cancer cells [20]. Furthermore, a complex of CDC42, 
PAR6, and PKCζ binds GSK3β and catalyzes the 
phosphorylation of Ser9 to inhibit GSK3β [21]. In order 
to associate PRKD1 with GSK3/β-catenin signaling, we 
performed western blot analysis. The results showed 
that reduction of PKD/PKCμ suppressed β-catenin 
expression and GSK3α and GSKβ phosphorylation 
(Figure 2A). These results were confirmed in control and 
PRKD1 siRNA-treated cells (Figure 2B). In addition, 
we confirmed that miR-34a expression levels were 
decreased by altering GSK3/β-catenin signaling following 
transfection with miR-34a inhibitors in MCF-7 cells, as a 
control (Supplementary Figure 3A, 3B).
PRKD1 expression and GSK3/β-catenin signaling 
were upregulated in MCF-7-ADR cells exhibiting 
tumorsphere formation (Figure 2C). Cancer stemness 
markers such as OCT4 and SOX2 were highly expressed in 
MCF-7-ADR cells in sphere status (Supplementary Figure 
4A, 4B). Furthermore, we also observed the expression 
of miR-34a was lower and the expression of PRKD1 was 
higher in MCF-7-ADR mammospheres compared with 
MCF-7 mammospheres (Supplementary Figure 5A, 5B). 
To investigate the effects of PRKD1 knockdown in breast 
cancer stemness, we performed a Tumorsphere formation 
assay. PRKD1 knockdown by miR-34a precursors and 
PRKD1 siRNA significantly decreased the number of 
tumorspheres (>70 μm) relative to controls (Figure 2D). 
Additionally, the BCSC population was determined 
by fluorescence-activated cell sorting analysis with 
staining for the BCSC markers CD44+/CD24-. The 
CD44+/CD24- population (Q1) was reduced by PRKD1 
knockdown (Figure 2E). Collectively, PRKD1 was capable 
of regulating cancer stemness in MCF-7-ADR cells by 
altering GSK3/β-catenin signaling.
Inhibition of PKD/PKCμ phosphorylation 
reduces BCSC self-renewal capacity
The processes associated with PKD/PKCμ 
phosphorylation were identified as two possible 
activation pathways: protein kinase C (PKC)-dependent 
phosphorylation (Ser744/Ser748) and autophosphorylation 
(Ser916). For full activation, autophosphorylation 
should occur immediately following PKC-dependent 
phosphorylation [10, 11]. CRT0066101 is an inhibitor 
that targets PKD autophosphorylation [16]. To determine 
the role of PKD/PKCμ autophosphorylation, MCF-7-
ADR cells were treated with 1 μM or 5 μM CRT0066101. 
Western blotting revealed that CRT0066101 inhibited 
phosphorylation of PKD/PKCμ and GSK3/β-catenin in 
MCF-7-ADR cells (Figure 3A). However, GSK3/β-catenin 
signaling was not influenced by CRT0066101 treatment in 
MCF-7 cells (Supplementary Figure 6A). The number of 
tumorspheres (>70 μm) following CRT0066101 treatment 
(1 μM or 5 μM) decreased in a dose-dependent manner 
relative to the control (Figure 3B). As expected, the 
CD44+/CD24- population (Q1) also decreased following 
treatment with 1 μM CRT0066101 (Figure 3C). These 
results indicated that regulation of breast cancer stemness 
is necessary for PKD/PKCμ autophosphorylation through 
GSK3/β-catenin signaling.
PRKD1 restores drug-resistance
Previous reports showed that PKD/PKCμ is 
involved in apoptosis through caspase-3 inhibition [22]. 
Therefore, we determined whether PRKD1 inhibition 
activates apoptosis in MCF-7-ADR cells, resulting in 
further reduction in breast cancer stemness. As shown in 
Figure 4A, exposure of MCF-7-ADR cells to doxorubicin 
(DOX) resulted in decreased cell survival rates in a dose-
dependent manner. Importantly, PRKD1 knockdown 
intensified the level of cell death as compared to control. 
To determine whether decreased cell survival was due 
to apoptosis, we measured casapase-3 activation. The 
results indicated that PRKD1 inhibition resulted in 
higher caspase-3 activity relative to control. Furthermore, 
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PRKD1 knockdown following DOX treatment enhanced 
caspase-3 activity relative to control cells treated with 
DOX (Figure 4B). Additionally, PRKD1 inhibition 
by 0.1–5 μM CRT0066101 decreased cell-viability 
percentages in a dose-dependent manner in MCF-7-ADR 
cells (Figure 4C), but cell viability rate was not relevant to 
treatment of CRT0066101 in MCF-7 cells (Supplementary 
Figure 6B). CRT0066101-treated cells combined with 
doxorubicin-induced apoptosis decreased cell viability 
to a greater degree than CRT0066101 treatment only 
Figure 2: Effects of PKD/PKCμ downregulation on breast cancer stemness through GSK3/β-catenin signaling in MCF-
7-ADR cells. All results were obtained from more than five independent transfection experiments. A-B. miR-34a precursor and PRKD1 
siRNAs (15 nM) were transfected into MCF-7-ADR cells and levels of miR-34a and PRKD1 expression confirmed by qRT-PCR. Western 
blot analysis of GSK3/β-catenin signaling. β-actin was used as the loading control. C. Basal phosphorylation and expression of PKD/PKCμ 
in tumorspheres from MCF-7-ADR cells as compared with two-dimensional cultured MCF-7 cells. D. Representative confocal images 
of tumorsphere formation were captured using an Olympus IX71 at a magnification of 400×. Scale bars represent 50 μm. E. Analysis of 
the cell-surface expression of mammary stem cell markers in MCF-7-ADR cell cultures. Histograms represent results of five independent 
experiments. Percentages indicate the number of cells in that quadrant. Bars represent each sample performed in triplicate and the error bars 
represent the ± S.D. * p < 0.05; ** p < 0.001; *** p < 0.0001.
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(Figure 4D). We also performed annexin V and propidium 
iodide (PI) staining to confirm that PRKD1 knockdown 
or inhibition of PKD/PKCμ phosphorylation enhanced 
apoptosis. The results showed that apoptosis initiation in 
miR-34a-precursor-treated, PRKD1 siRNA-treated, and 
DOX-treated cells increased relative to that in controls. 
Interestingly, the apoptosis levels increased following 
CRT0066101 treatment of DOX-treated cells (Figure 4E). 
Together, these data indicated that downregulated PRKD1 
or inhibition of PKD/PKCμ autophosphorylation restored 
drug-resistance in MCF-7-ADR cells.
Figure 3: Effects of CRT0066101 on breast cancer stemness through GSK3/β-catenin signaling in MCF-7-ADR cell 
lines. A. Western blot analysis of GSK3/β-catenin signaling following treatment with 0.1–10 μM of CRT0066101. Blots are representative 
of five independent experiments. β-actin was used as the loading control. B. Tumorsphere cells were treated with distilled water (control) 
or 1 μM or 5 μM CRT0066101. Representative confocal images of tumorsphere formation were captured using an Olympus IX71 at 
a magnification of 400×. Scale bars represent 50 μm. The graph shows the numbers of tumorspheres per 2000 cells. C. Analysis of 
cell-surface expression of CD44+/CD24- on MCF-7-ADR cells following CRT0066101 treatment. Histograms represent results of three 
independent experiments. Percentages indicate the number of cells in that quadrant. * p < 0.001; ** p < 0.0001; *** p < 0.0001.
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Figure 4: Influence of PKCμ inhibition on MCF-7-ADR cell apoptosis. A. Cell-viability percentages were detected following 
transfection of MCF-7-ADR cells with control vector or PRKD1 siRNA. Cells were treated with doxorubicin after knockdown of PRKD1 
expression in a dose-dependent manner. B. The level of caspase-3 activity measured following PRKD1 downregulation and PRKD1 
downregulation following doxorubicin treatment. C. WST-8 assay following CRT0066101 treatment (0.1–5 μM) and 70-h incubation in 
MCF-7-ADR cells. Optical density was measured at 450 nm. D. Caspase-3 activation measured with a colorimetric assay following treatment 
with 1 μM or 2 μM CRT0066101, or 10 μM doxorubicin. Relative caspase-3 activities were measured at 405 nm. E. Representative images 
of annexin V/PI-stained cells captured by confocal microscopy at a magnification of 200×. Scale bars represent 50 μm. Data represent the 
mean ± S.D. * p < 0.05; ** p < 0.001.
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PKCμ functional inhibition or downregulation 
suppresses tumor growth in xenograft models
In our previous study, we confirmed that miR-34a 
suppressed NOTCH1 expression, leading to inhibition of 
tumor formation in nude mice [5]. Here, we determined 
whether PRKD1 downregulation by miR-34a would 
suppress tumor growth in xenograft models. The level 
of PRKD1 expression was downregulated in miR-34a-
overexpressed tumors relative to control tumors (Figure 
5A). Immunohistochemistry (IHC) staining showed that 
PKCμ and proliferating cell nuclear antigen (PCNA) were 
decreased in miR-34a-overexpressed tumors (Figure 5B). 
To determine whether PRKD1 suppression by miR-34a 
Figure 5: PKCμ downregulation suppresses tumor formation in xenograft models. A. PRKD1 mRNA expression was 
quantified by qRT-PCR from control and miR-34a overexpressed tumors. B. Immunohistochemistry was performed to detect the expression 
of PKCμ and PCNA in control and miR-34a-overexpressed tumors. Magnification at 200×; scale bars represent 10 μm. C. TUNEL assay 
and DAPI staining was performed. Magnification at 400×; scale bars represent 20 μm. D. CRT0066101 (65 mg/kg) orally administered 
to treat established tumors in nude mice daily for 4 weeks. Representative xenografts from three mice. E. Decrease in tumor volumes 
of CRT0066101-treated tumors relative to control tumors. However, any alterations weren’t detected in weight of mice. F. Western blot 
analysis of phosphorylated PRKD1 and GSK3/β-catenin signaling. β-actin was used as the loading control. G. Immunofluorescence images 
showing TUNEL assay and Ki67 in control and CRT0066101-treated tumors. Data are presented as means ± S.D. * p < 0.05, ** p < 0.001.
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would repress tumor growth via apoptosis, we performed 
a terminal deoxynucleotidyl transferase dUTP nick-end 
labeling (TUNEL) assay. The results revealed that miR-
34a-overexpressed tumors contained higher numbers of 
apoptotic cells as compared to control tumors (Figure 5C). 
To further evaluate the effects of PKD/PKCμ functional 
inhibition, we orally treated mice with established tumors 
in xenograft models of MCF-7-ADR cells with a dose of 65 
mg/kg CRT0066101 daily for 4 weeks. The size of tumors 
in mice treated with CRT0066101 decreased relative to 
untreated controls (Figure 5D). As expected, the weight of 
tumors from mice treated with CRT0066101 decreased as 
compared to that of control tumors. CRT0066101 treatment 
didn’t cause side effects such as remarkable signs of toxicity 
and loss of weight in all the animals. (Figure 5E). Moreover, 
downregulation of phosphorylated PKD/PKCμ through 
GSK3/β-catenin signaling was also confirmed by western 
blot analysis (Figure 5F). Finally, we performed TUNEL 
assay and Ki-67 staining to confirm CRT0066101 enhanced 
apoptosis and repressed proliferation. The results indicated 
that CRT0066101 treated tumors were increased apoptosis 
and decreased proliferation relative to controls (Figure 5G). 
Altogether, PKCμ inhibition by miR-34a or CRT0066101 
contributed to reduction of tumor growth through apoptosis 
initiation in vivo.
DISCUSSION
PRKD1 is involved in cell proliferation, apoptosis, 
cell adhesion, invasion, and vesicle trafficking [23]. 
Interestingly, PRKD1 expression exhibits different pattern 
in various cancer cell types and displays dual functions as 
an oncogene or tumor suppressor [24]. PRKD1 expression 
is downregulated in invasive human breast tumors 
as compared with normal breast tissue [25]. Similar 
expression patterns were confirmed by microarray analysis 
and invasive cellular models, such as SK-BR-3, T-47D, 
and MDA-MB-231 [25, 26]. Furthermore, reversion of 
PRKD1 promoter methylation blocks breast cancer cell 
invasion and metastasis [27]. Our results showed that 
patterns of PRKD1 expression increased drug resistance in 
MCF-7-ADR cell lines. PRKD1 was highly expressed in 
drug resistance cell lines including doxorubicin-resistance 
MCF-7-ADR cells, tamoxifen-resistance LCC2 cells, 
and tamoxifen and fluvestrance resistance LCC9 cells 
(data were not shown). Therefore, we conclude PRKD1 
expression is associated with drug resistance properties. 
We investigated the expression of miR-34a and PRKD1 
in TCGA data sets (Supplementary Figure 7A). Since 
PRKD1 is highly expressed in drug-resistance breast 
cancer cells, we couldn’t find the inverse correlation 
between miR-34a and PRKD1 expression in TCGA 
DB. We further confirmed overall survival according to 
level of PRKD1 expression in TCGA clinical data sets 
(Supplementary Figure 7B). This graph represents patients 
with high PRKD1 expression had poor survival than those 
with low expression. Although we couldn’t confirmed 
that inverse correlation between miR-34a and PRKD1 
expression in whole breast cancer samples, we derived 
PRKD1 expression correlates with worse prognosis of 
Figure 6: Hypothetical schematic pathway. miR-34a directly suppresses PRKD1 and CRT0066101 inhibits autophosphorylated 
PKD/PKCμ. The two directions represent differential regulation of self-renewal capacity in BCSC and drug resistance in MCF-7-ADR 
cells through GSK3/β-catenin signaling.
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breast cancer patients. Furthermore, we confirmed that 
downregulated PRKD1 altered apoptosis signaling. 
Therefore, we suggest that PRKD1 may be a potential 
option for the restoration of drug sensitivity in breast 
cancer cells.
The microRNA miR-34a plays a key role in 
suppressing tumor. Previous studies reported that miR-
34a inhibits CSC function in various cancer types, 
including prostate cancer [28], pancreatic cancer [29], 
medulloblastomas [30], and glioblastomas [31]. This 
molecule also suppresses targets associated with the cell 
cycle, differentiation, and apoptosis, while inhibiting 
cancer-cell viability, cancer stemness, metastasis, and 
chemoresistance [17]. Here, we confirmed that miR-
34a negatively regulates PRKD1 in MCF-7-ADR cells. 
Additionally, we found that PRKD1 is a novel target 
of miR-34a through its binding to the PRKD1 3′-UTR. 
Furthermore, we established that miR-34a-PRKD1 
interactions play a critical role in overcoming cancer 
stemness and drug resistance in breast cancer cell lines. 
Prior studies reported that PRKD1 phosphorylates 
β-catenin at Thr112/Thr120 and that PRKD1 
overexpression resulted in suppression of β-catenin-
mediated transcriptional activity [32]. Phosphorylation 
of β-catenin is occurs through GSK3, which targets 
β-catenin as part of the Wnt-signaling protein complex 
[33]. Furthermore, GSK3β is a kinase involved in 
prostate cancer stemness and migration through a Wnt-
independent mechanism [34]. In our study, we observed 
that downregulated PRKD1 led to suppression of the self-
renewal capacity of BCSCs through alteration of GSK3/
β-catenin signaling. Therefore, these results indicate that 
PRKD1 activates breast cancer stemness through GSK3/β-
catenin signaling.
Harikumar et al. discovered CRT0066101 as a 
specific inhibitor of all PKD isoforms [16], showing 
that CRT0066101 blocks pancreatic cancer growth by 
inhibiting PRKD1 autophosphorylation [16]. Here, 
we confirmed that PRKD1 activation was blocked by 
CRT0066101 treatment of breast cancer cell lines and 
xenograft models. These results provide the first evidence 
that CRT0066101 may constitute a potential therapeutic 
agent for breast cancer patients.
In this study, we showed that PRKD1 overexpression 
in MCF-7-ADR cell lines was negatively correlated with 
miR-34a overexpression. We confirmed miR-34a binding 
to the PRKD1 3′-UTR, resulting in suppression of cancer 
stemness in BCSCs through the GSK3/β-catenin signaling 
pathway. Furthermore, we reported that CRT0066101, a 
known PRKD1 inhibitor, influenced reductions in BCSC 
population and drug resistance through the GSK3/β-
catenin signaling pathway (Figure 6). Furthermore, 
we observed that ectopic expression of miR-34a and 
CRT0066101 treatment prevented tumor growth in 
xenograft models. In conclusion, PRKD1 is negatively 
regulated by miR-34a, leading to suppression of cancer 
stemness and drug resistance in breast cancer cell lines. 
These findings provide evidence that PRKD1 is a key 
molecule that activates breast cancer stemness and drug 




CRT0066101 was purchased from R&D Systems 
(Minneapolis, MN, USA); the drug was resuspended 
in autoclaved distilled water for in vivo studies. For 
CRT0066101 treatment, MCF-7-ADR cells (American 
Type Culture Collection, Manassas, VA, USA) were 
seeded and 0.1–10 μM CRT0066101 was added, 
followed by incubation for 1 h. WST-8 was purchased 
from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). 
PRKD1 siRNA and scrambled siRNA (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) were transfected 
using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, 
CA, USA).
Cell culture and transfection
The human breast adenocarcinoma MCF7, MCF-
7-ADR, and MDA-MB-231 cell lines (American Type 
Culture Collection) were grown in Dulbecco's modified 
Eagle’s Medium (DMEM; Welgene, Daejeon, South 
Korea) and supplemented with 10% fetal bovine serum 
(FBS; Welgene) and 1% penicillin streptomycin in a 
37°C humidified incubator under 5% CO2. MCF-7-ADR 
cells were seeded on 10-cm plates in media lacking 
antibiotics in preparation for RNAi transfection. After 24 
h, the cells were transfected with PRKD1 siRNA using 
Lipofectamine RNAiMAX (Invitrogen). After 48 h, the 
cells were collected for western blot analysis or were 
resuspended in mammosphere medium. For microRNA 
transfection, MCF-7-ADR cells were seeded for 48 h with 
miRNA precursors (miR-34a/b/c) using siPORT NeoFX 
Transfection Agent (Ambion; Thermo Fisher, St. Louis, 
MO, USA). The miRNA precursors and negative-control 
precursors were also obtained from Thermo Fisher.
Quantitative reverse-transcription PCR 
(qRT-PCR)
The qRT-PCR was performed using a RG3000 
instrument (Corbett Robotics, San Francisco, CA, USA) 
with the SYBR Green-based procedure according to 
manufacturer instructions. The ABI-7500 instrument 
(Thermo Fisher) was used to assess PRKD1 expression 
in various breast-cancer cell lines. All oligonucleotide 
primers were designed using DNASTAR (Madison, 
WI, USA). All qRT-PCR graphs were obtained using 
comparative Ct (ΔΔCt).
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Western blotting and antibodies
A total of 30 μg of protein extract was separated by 
8% SDS-PAGE and the proteins were electrotransferred 
to PVDF membrane. The primary antibodies used 
were: phosphorylated PKD/PKCμ (Ser916), GSK3β, 
phosphorylated GSK3α (Ser21)/β (Ser9), and β-catenin 
were purchased from Cell Signaling Technology (Danvers, 
MA, USA) and the antibody against PKD/PKCμ was 
obtained from Santa Cruz Biotechnology. β-Actin (Bethyl 
Laboratories, Montgomery, TX, USA) was used as the 
loading control. The membranes were washed with 1× 
PBS/0.1% Tween 20, and bound proteins were detected 
by enhanced chemiluminescence (Amersham Pharmacia 
Biotech, Parsippany, NJ, USA).
Luciferase assay
The 3′-UTR reporter constructs for PRKD1 were 
cloned into a pGL3-Control vector and the 3′-UTRs 
of PRKD1 were amplified from the genomic DNA of 
HEK293T cells. The seed sequences of miR-34 from 
PRKD1 were mutated using PCR-based methods and 
the reporter constructs were verified by sequencing. 
HEK293T cells were transiently transfected with 3′-
UTR reporter constructs (1.5 μg/well in 6-well plates) 
and 15 nM of miR-34 family precursors (Ambion), using 
Lipofectamine 2000 (Invitrogen). The activity of 3′-UTR 
reporter constructs was normalized to the activity of the 
cotransfected pCMV-hRL (40 ng/well in 6-well plates, 
Promega). After a 24-h incubation, cells were lysed using 
1× passive lysis buffer and activity was measured using 
the Dual Luciferase Assay kit (Promega) according to 
manufacturer instructions.
Tumorsphere formation assay (TSA)
For the tumorsphere culture, cells (2000 cells/
mL) were cultured in suspension in serum-free DMEM/
F12 (welGENE) supplemented with 1% penicillin, B27 
(1:50; Gibco; Thermo Fisher), 20 ng/mL epidermal growth 
factor (Prospec, East Brunswick, NJ, USA), 5 mg/mL 
insulin (Sigma-Aldrich, St. Louis, MO, USA), and 0.4% 
bovine serum albumin (Sigma-Aldrich). After ~10 days, 
plates were analyzed for tumorsphere formation and were 
quantified using a microscope (Olympus IX71; Olympus, 
Tokyo, Japan). For counting tumorspheres, MCF-7-
ADR cells were filtered through a 70-μm pore strainer 
(BD Biosciences, East Rutherford, NJ, USA) and then 
quantified. CRT0066101 treatment was administered at 
culture days 6 and 8.
Surface marker analysis by flow cytometry
We assessed expression of CD44+/CD24- surface 
markers by collecting cells after transfection with 
PRKD1 RNAi or treatment with CRT0066101. Cells 
were washed with PBS with 2% FBS, stained with anti-
CD44 (APC-conjugated; BD Biosciences) and anti-CD24 
(PE-conjugated; BD Biosciences) in PBS with 2% FBS, 
and incubated on ice in the dark for 30 min. Cells were 
washed again with cold PBS buffer and analyzed by flow 
cytometry after loading >10,000 cells into a BD CantoII 
flow cytometer (BD Biosciences) using FACSDiVa 
software (BD Biosciences).
Cell-viability assay
MCF-7-ADR cells were plated in 24-well plates and 
incubated with various concentrations (0.1, 0.5, 1, 5, 10 μM) 
of CRT0066101 for 72 h. Cell viability was determined by a 
WST-8 assay (Sigma-Aldrich), and optical density measured 
at 450 nm using a microplate reader.
Fluorescent immunohistochemistry
Paraffin sectioned slides from control or miR-
34a overexpressed tumors and vehicle or CRT0066101 
treated tumors were used. Slides were deparaffinized and 
rehydrated in Histoclear (3-4 times), then passed through 
a graded ethanol series (100%, 95%, 80%, 70%) in order. 
Antigen retrieval was performed by dipping the sections 
into 0.01M citric acid solution (pH6.0) and boiling in 
the microwave for 15mins. In case of TUNEL assay, 
In situ cell Death Detection Kit, Fluorescein (Roche, 
Indianapolis, USA) labeled apoptotic positive cells and 
Ki-67 primary antibody (Vector Lab, USA) was applied 
onto the section, and it was incubated in 4°C overnight. 
Then, the slides were incubated with DAPI and secondary 
antibody for 2h. Finally, mounted with mounting solution 
(Dako) and images were captured with a confocal 
microscope (Zeiss).
Preparation of breast cancer xenografted mice
All studies involving the use of nude mice were 
approved by the Animal Care and Use Committee of 
Yonsei University Medical School (2015-0087) and 
performed in specific pathogen-free facilities and under 
conditions in accordance with the Guidelines for the Care 
and Use of Laboratory Animals of YUMS. Mice were 
inoculated subcutaneously with 1.5x106 MCF-7-ADR 
cells into each flank under 150 μL of saline/zoletil/rompun 
(7:1:1) anesthesia. Mice were randomized into groups (n = 
6 per group), and treatment was started 10 days after tumor 
implantation. CRT0066101 was administered to tumor-
bearing animals orally, five times a week for 4 weeks at 
dose of 1.6mg/kg. From palpable tumor formation until 
termination, tumor sizes were measured every 3 to 4 days 
using calipers, and tumor volume was calculated with 
the following formula: length × width2 × 0.5236. Mice 
were sacrificed in a 7.5% CO2 chamber, and tumors were 
harvested for immunohistochemistry and other analyses.
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